Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;60(4):1215-1219.

Immunoexpression of E-, P- and N-cadherins in ovarian serous malignant tumors

Affiliations
  • PMID: 32239097
Free article

Immunoexpression of E-, P- and N-cadherins in ovarian serous malignant tumors

Corina Maria Dochiţ et al. Rom J Morphol Embryol. 2019.
Free article

Abstract

Alteration of cadherin immunophenotype is associated with the epithelial-mesenchymal transition, a complex biomolecular mechanism involved in carcinomas progression. The study investigated the immunoexpression of E-, P- and N-cadherins in 50 serous malignant tumors of ovary related to the histopathological prognostic parameters of the lesions, using a quantification based on scores that took into account the number of marked cells and the intensity of the reactions. The E-cadherin and P-cadherin immunostainings were significantly superior in serous borderline tumors (SBTs) compared to carcinomas, as well as in advanced carcinomas compared to early stages. Although the immunoreactions indicated higher scores in high-grade serous carcinomas (HGSCs) versus low-grade ones (LGSCs), the aspect was without statistical significance. Immunoreactions of N-cadherin were present only in HGSC, being significantly superior in the advanced stages of tumors. Ovarian serous malignant tumors expressed E-, P- and N-cadherins in different proportions, the altered cadherin phenotype being associated with progression of the disease. The results can be used to identify tumors with progression potential and to better stratify patients for specific therapy.

PubMed Disclaimer

LinkOut - more resources